1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU HTA Regulation: Industry’s Missed Opportunity & The PICO Process

 
• By Francesca Bruce

Pharmaceutical companies missed a big opportunity to help shape the scoping process for the forthcoming EU-level joint clinical assessments, but they can still contribute to how the process develops, according to Niklas Hedberg, formerly chair of the recently concluded European Network for Health Technology Assessments.

Close-up of European Names on Maps
Industry can still contribute to developing the scoping system for the EU-level joint clinical assessments • Source: Shutterstock

Companies concerned about European countries using PICO (population, intervention, comparator, outcomes) surveys to help frame the parameters of the EU-level joint clinical assessments (JCA) that will be conducted under the Health Technology Assessment (HTA) Regulation should rest assured.

This was the message from Niklas Hedberg, co-chair of the Co-ordination Group established to oversee JCAs and other elements of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By Vibha Sharma

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 
• By Francesca Bruce

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

More from Geography

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By Vibha Sharma

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 
• By Francesca Bruce

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 
• By Francesca Bruce

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.